CRISPR, CAR T and mRNA: Scrutinizing Recent Life Sciences IP Controversies to Develop a New Way Forward
Mary Ferguson, Ph.D.
Senior Vice President, Head of IP
Lisa Hillman, Ph.D.
Lathrop GPM LLP
Thomas J. Kowalski
Duane Morris LLP
Kevin E. Noonan, Ph.D.
McDonnell Boehnen Hulbert & Berghoff LLP
Securing IP rights to novel therapeutics and technologies like CRISPR, CAR T and mRNA and leveraging or licensing these rights appropriately is essential to successful commercialization, growth, and future development of these innovations. This session will review the current landmines and hurdles in the biotech space and then provide an insightful exchange on obtaining and enforcing biotech patents.
- Newest prosecution strategies for CRISPR, CAR T and mNRA therapies and products
- Emphasizing the importance of including a claim on any medical devices incorporated into the biotech invention
- Responding to novelty and subject matter eligibility rejections from the USPTO
- CRISPR licenses: update on the Broad Institute patent legal battle
- Best practices for licensing and collaborations with biotech
- Considering the biotech patent landscape in non-US jurisdictions